Clinical Trial Update: Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA) [Phase 4]

View source ↗

Summary

A Phase 4 trial (AFORA) evaluated whether serum adalimumab concentration can predict clinical outcomes in rheumatoid arthritis. The study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: University Hospital, Tours | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED